Literature DB >> 14555975

Induction of in vitro nuclear apoptosis activity coincides with the production of 50 kDa cytosolic protein.

M Naito1, K Shiina, T Mashima, K Nagashima, T Tsuruo.   

Abstract

Human monocytic leukemia U937 cells undergo apoptosis when cells are treated with the anticancer drug etoposide. To study the mechanism of drug-induced apoptosis, we used an in vitro apoptosis system with cytosol from etoposide-treated U937 cells. The cytosol from apoptotic U937 cells showed activity to induce morphologic changes and oligonucleosomal DNA fragmentation in isolated nuclei in vitro; both are typical features of apoptosis. We generated monoclonal antibodies to the proteins in the etoposide-treated U937 cytosol. We found that a 50 kDa protein, recognized by SN-1 monoclonal antibody, appeared in the cytosol of U937 cells, in accordance with its cell-free apoptosis activity. Z-Asp, an inhibitor of interleukin-1beta converting enzyme (ICE) family proteases, inhibited the appearance of the 50 kDa protein and the emergence of the cell-free apoptosis activity in the etoposide-treated U937 cytosol. These results indicate that the 50 kDa protein is produced by the activation of ICE family protease during apoptosis and suggest some roles of the protein in the development of apoptosis.

Entities:  

Year:  1997        PMID: 14555975     DOI: 10.1038/sj.cdd.4400287

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  2 in total

1.  Could 99mTc-glucarate be used to evaluate tumour necrosis? In vitro and in vivo studies in leukaemic tumour cell line U937.

Authors:  Nathalie Perek; Odile Sabido; Nathalie Le Jeune; Nathalie Prevot; Jean-Michel Vergnon; Anthony Clotagatide; Francis Dubois
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-13       Impact factor: 9.236

2.  American ginseng stimulates insulin production and prevents apoptosis through regulation of uncoupling protein-2 in cultured beta cells.

Authors:  John Zeqi Luo; Luguang Luo
Journal:  Evid Based Complement Alternat Med       Date:  2006-09       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.